Ucb S A (UCBJF) 71.4900 $UCBJF Dr. Reddy's (RDY)

Ucb S A (UCBJF) 71.4900 $UCBJF

Dr. Reddy's (RDY) Acquires Ducere Pharma's OTC Brands
Zacks Equity Research - Zacks Investment Research - Thu May 26, 2:57PM CDT
Dr. Reddy's Laboratories Ltd. (RDY) announced that it acquired a portfolio of OTC brands in the cough-and-cold, pain, and dermatology categories from Ducere Pharma.
ABT: 39.18 (-0.35), JNJ: 114.76 (+0.27), RDY: 46.97 (-0.10)

UCB (UCBJF) Posts Q1 Results, Reiterates 2016 Guidance
Zacks Equity Research - Zacks Investment Research - Tue Apr 26, 10:23AM CDT
UCB (UCBJF) reported interim results for the first three months of 2016.
EBS: 43.71 (+0.07), GILD: 86.15 (-0.57), SHPG: 192.14 (+2.10)

UCB: CONVENING NOTICE TO ATTEND THE GENERAL MEETING OF SHAREHOLDERS
Globe Newswire - Fri Mar 25, 3:01AM CDT
*** Unofficial English translation - For convenience purposes only ***

Dr. Reddy's Q3 Earnings Up Y/Y, Warning Letter in Focus
Zacks Equity Research - Zacks Investment Research - Wed Feb 10, 10:06AM CST
Dr. Reddy's Laboratories Ltd. (RDY) reported third-quarter fiscal 2016 earnings per American Depositary Share of 51 cents, up 1% from the year-ago quarter.
ATRA: 18.17 (-0.96), BXLT: 46.02 (-0.18), RDY: 46.97 (-0.10)

ZS Pharma Soars on $2.7B Buyout Offer from AstraZeneca
Zacks Equity Research - Zacks Investment Research - Mon Nov 09, 11:50AM CST
AstraZeneca (AZN) will acquire biotech company ZS Pharma (ZSPH) for about $2.7 billion, boosting its cardiovascular & metabolic disease portfolio and pipeline.
ZSPH: 89.98 (+0.06), AZN: 29.73 (+0.06)

Aerie (AERI) Posts Narrower-than-Expected Loss in Q3
Zacks Equity Research - Zacks Investment Research - Wed Nov 04, 9:40AM CST
Aerie (AERI) reported third-quarter 2015 loss of 69 cents per share, much narrower than the Zacks Consensus Estimate of a loss of 81 cents.
ADHD: 5.44 (-0.06), AERI: 18.29 (-0.77), SPPI: 7.34 (-0.18)

Dr. Reddy's (RDY) Q2 Earnings Rise Y/Y, Biosimilars in Focus
Zacks Equity Research - Zacks Investment Research - Fri Oct 30, 10:16AM CDT
Dr. Reddy's Laboratories (RDY) reported second-quarter fiscal 2016 earnings per American Depositary Share (ADS) of 64 cents, up 25.5% from the year-ago quarter.
ANAC: 99.30 (unch), RDY: 46.97 (-0.10), CORT: 5.82 (-0.43)

Valeant (VRX) Loses Over 5% Despite Business Model Review
Zacks Equity Research - Zacks Investment Research - Tue Oct 27, 1:22PM CDT
Investigations into Valeant's (VRX) drug pricing policies and accusations related to its business model continue. The company has an uphill battle ahead.
LCI: 24.61 (-0.21), VRX: 28.87 (-0.54), ANAC: 99.30 (unch)

Valeant (VRX) in Focus on Intensifying Government Probe
Zacks Equity Research - Zacks Investment Research - Fri Oct 16, 1:20PM CDT
Valeant (VRX) has hit a rough patch ever since concerns arose about the irrational increase in drug prices by U.S. pharma/biotech companies.
LCI: 24.61 (-0.21), VRX: 28.87 (-0.54), ANAC: 99.30 (unch)

Prothena to Start Phase IIb Study on AL Amyloidosis Drug
Zacks Equity Research - Zacks Investment Research - Fri Oct 16, 1:10PM CDT
Prothena (PRTA) announced that it will commence a phase IIb study on NEOD001 for patients suffering from AL amyloidosis and persistent cardiac dysfunction.
LCI: 24.61 (-0.21), ANAC: 99.30 (unch), PRTA: 48.41 (-1.91)

Shire's Cinryze Gets Fast Track Status for Additional Indication
Zacks Equity Research - Zacks Investment Research - Wed Oct 14, 2:45PM CDT
Shire announced that its HAE drug Cinryze has been granted Fast Track designation for antibody mediated rejection (AMR) in renal transplant recipients by the FDA.
LCI: 24.61 (-0.21), SHPG: 192.14 (+2.10), AZN: 29.73 (+0.06)

UCB Reveals Positive Data on Vimpat Monotherapy Study
Zacks Equity Research - Zacks Investment Research - Thu Oct 08, 1:45PM CDT
UCB (UCBJF) announced encouraging top-line results from a phase III non-inferiority study on Vimpat monotherapy for newly diagnosed partial-onset seizures.
ADHD: 5.44 (-0.06), APRI: 0.44 (unch), ANAC: 99.30 (unch)

Catalyst Starts Congenital Myasthenic Syndromes Study
Zacks Equity Research - Zacks Investment Research - Wed Oct 07, 1:35PM CDT
Catalyst Pharmaceuticals (CPRX) initiated a pediatric study on Firdapse for congenital myasthenic syndromes in patients aged 2 years to 17 years.
BMRN: 90.00 (-1.52), CPRX: 0.61 (-0.02), APRI: 0.44 (unch)

Lannett (LCI) to Buy UCB's Specialty Generics Subsidiary
Zacks Equity Research - Zacks Investment Research - Thu Sep 03, 3:10PM CDT
Lannett Company (LCI) inked a deal with UCB to buy its U.S. specialty generics subsidiary, Kremers Urban Pharmaceuticals Inc.
LCI: 24.61 (-0.21), JNJ: 114.76 (+0.27), CORT: 5.82 (-0.43)

Amgen, Novartis Team Up; Bone Drug Positive in Phase III
Zacks Equity Research - Zacks Investment Research - Wed Sep 02, 3:50PM CDT
Amgen (AMGN) inks deal with Novartis for Alzheimer's disease and migraine; reports positive phase III data on romosozumab.
AMGN: 159.19 (-0.68), LLY: 75.12 (-0.34), NVS: 80.95 (+0.24)

Dr. Reddy's Q1 Earnings & Revenues Rise Y/Y, Offers View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 31, 2:07PM CDT
Dr. Reddy's Laboratories (RDY) reported first-quarter fiscal 2016 earnings per American Depositary Share (ADS) of 58 cents, up 13.7% from the year-ago quarter.
AGN: 246.96 (-0.16), PGNX: 4.94 (-0.07), RDY: 46.97 (-0.10)

UCB to Expand Cimzia Label Based on Positive Phase III Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 15, 1:50PM CDT
UCB S.A. (UCBJF) announced positive results from a phase III study on Cimzia for rheumatoid arthritis in DMARD-naive patients at high risk of disease progression.
VRX: 28.87 (-0.54), BIOD: 0.35 (+0.01)

Immunomedics' Drug Gets Fast Track Status for Lung Cancer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 18, 3:39PM CDT
Immunomedics, Inc. (IMMU) announced that the FDA has granted fast track designation to its lead antibody-drug conjugate program sacituzumab govitecan for the treatment of patients suffering from metastatic non-small cell lung cancer.
VRX: 28.87 (-0.54), IMMU: 4.52 (-0.78), PFE: 34.69 (-0.18)